MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
56.15
+2.24
+4.16%
After Hours: 55.06 -1.09 -1.94% 19:17 02/06 EST
OPEN
55.16
PREV CLOSE
53.91
HIGH
56.45
LOW
54.32
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
91.77
52 WEEK LOW
27.66
MARKET CAP
7.35B
P/E (TTM)
-11.6058
1D
5D
1M
3M
1Y
5Y
1D
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline
Simply Wall St · 16h ago
XBI, PCVX, MIRM, RVMD: Large Outflows Detected at ETF
NASDAQ · 2d ago
Vaxcyte to Present at Guggenheim Emerging Outlook Biotech Summit
Reuters · 3d ago
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
TipRanks · 5d ago
Vaxcyte nimmt durch Aktienemission 600 Millionen Dollar ein
Reuters · 6d ago
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Barchart · 6d ago
Vaxcyte Price Target Maintained With a $116.00/Share by Guggenheim
Dow Jones · 6d ago
Guggenheim Reiterates Buy on Vaxcyte, Maintains $116 Price Target
Benzinga · 6d ago
More
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.